NO20004222L - HLA-koblet pre-eklampsi- og abort-mottagelighetsgen - Google Patents

HLA-koblet pre-eklampsi- og abort-mottagelighetsgen

Info

Publication number
NO20004222L
NO20004222L NO20004222A NO20004222A NO20004222L NO 20004222 L NO20004222 L NO 20004222L NO 20004222 A NO20004222 A NO 20004222A NO 20004222 A NO20004222 A NO 20004222A NO 20004222 L NO20004222 L NO 20004222L
Authority
NO
Norway
Prior art keywords
eclampsia
abortion
hla
susceptibility gene
linked pre
Prior art date
Application number
NO20004222A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004222D0 (no
Inventor
Margaret O'brien
John Bermingham
Kathleen A Quane
David M Jenkins
Tommie V Mccarthy
Original Assignee
Nat Univ Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Ireland filed Critical Nat Univ Ireland
Publication of NO20004222D0 publication Critical patent/NO20004222D0/no
Publication of NO20004222L publication Critical patent/NO20004222L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
NO20004222A 1998-02-25 2000-08-23 HLA-koblet pre-eklampsi- og abort-mottagelighetsgen NO20004222L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE980134 1998-02-25
IE980668 1998-08-12
PCT/IE1999/000012 WO1999043851A1 (fr) 1998-02-25 1999-02-25 Gene de susceptibilite a la pre-eclampsie et aux fausses-couches lie au hla

Publications (2)

Publication Number Publication Date
NO20004222D0 NO20004222D0 (no) 2000-08-23
NO20004222L true NO20004222L (no) 2000-10-24

Family

ID=26320158

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004222A NO20004222L (no) 1998-02-25 2000-08-23 HLA-koblet pre-eklampsi- og abort-mottagelighetsgen

Country Status (6)

Country Link
EP (1) EP1056886A1 (fr)
JP (1) JP2003517267A (fr)
AU (2) AU2636399A (fr)
CA (1) CA2321223A1 (fr)
NO (1) NO20004222L (fr)
WO (1) WO1999043851A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586177B1 (en) * 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
ATE313799T1 (de) * 1999-09-27 2006-01-15 Clifford L Librach Nachweis von hla-g
DE19952509A1 (de) * 1999-11-03 2001-05-31 Grosse Wilde Hans Nachweis und Verwendung löslicher HLA-G Moleküle
FR2810047B1 (fr) * 2000-06-13 2004-04-02 Commissariat Energie Atomique Nouvelle isoforme d'hla-g et ses applications
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
WO2005108624A2 (fr) * 2004-05-06 2005-11-17 University Of Chicago, Uctech Utilisation du genotypage hla-g dans des affections d'origine immunologiques
WO2006047787A2 (fr) 2004-10-27 2006-05-04 Exact Sciences Corporation Methode de surveillance de la progression ou la recurrence d'une maladie
WO2006069592A2 (fr) * 2004-12-31 2006-07-06 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Methode permettant de diagnostiquer et/ou de predire la toxemie preeclamptique et/ou des troubles associes
CA3007182A1 (fr) * 2005-03-18 2006-09-21 The Chinese University Of Hong Kong Marqueurs de diagnostic prenatal, de surveillance ou de prediction de lapreeclampsie
WO2007044071A2 (fr) 2005-04-21 2007-04-19 Exact Sciences Corporation Analyse d'echantillons d'acide nucleique heterogenes
US20090156532A1 (en) * 2006-01-24 2009-06-18 The University Of Chicago SNP BINDING SITE FOR microRNAs IN HLA-G
US20090317812A1 (en) * 2006-06-30 2009-12-24 Librach Clifford L Method of detecting preeclampsia
EP1944611A1 (fr) * 2007-01-11 2008-07-16 Université de la Méditerranée Biomarqueur pour la médecine et la biologie de la reproduction
JP2010528629A (ja) 2007-06-07 2010-08-26 シモンズ ハプロミクス リミテッド 遺伝子地図作製及びハプロタイプ決定のための現場（ｉｎｓｉｔｕ）法
GB0804662D0 (en) * 2008-03-13 2008-04-16 Guy S & St Thomas S Nhs Founda Drug response marker
CN104777307B (zh) * 2008-10-31 2019-10-18 耶鲁大学 先兆子痫检测和治疗的方法和组合物
FR2953023B1 (fr) * 2009-11-23 2011-12-09 Commissariat Energie Atomique Utilisation d'une isoforme d'hla-g comme marqueur de l'osteogenese
US10131947B2 (en) * 2011-01-25 2018-11-20 Ariosa Diagnostics, Inc. Noninvasive detection of fetal aneuploidy in egg donor pregnancies
EP3648110A1 (fr) * 2018-11-02 2020-05-06 Immune Compass Ltd. Système de criblage d'un trouble lié au système immunitaire
CA3145620A1 (fr) * 2019-07-05 2021-01-14 Intellexon Gmbh Hla-h en medecine et diagnostic
US20220380848A1 (en) * 2019-10-25 2022-12-01 Intellexon Gmbh Hla class i molecules in in vitro fertilization and further medical implications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717498B1 (fr) * 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcrits du gène de CMH de classe I HLA-G et leurs applications.
CA2190576A1 (fr) * 1994-05-18 1995-11-23 Rafik R. Ghobrial Antigenes chimeres de classe i du complexe majeur d'histocompatibilite induisant une tolerance aux allogreffes
JPH11503320A (ja) * 1995-04-07 1999-03-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｈｌａ−ｇ検出用抗体

Also Published As

Publication number Publication date
AU2636399A (en) 1999-09-15
EP1056886A1 (fr) 2000-12-06
JP2003517267A (ja) 2003-05-27
CA2321223A1 (fr) 1999-09-02
WO1999043851A1 (fr) 1999-09-02
AU2003231618A1 (en) 2003-09-11
NO20004222D0 (no) 2000-08-23

Similar Documents

Publication Publication Date Title
NO20004222L (no) HLA-koblet pre-eklampsi- og abort-mottagelighetsgen
DE69842016D1 (de) Mikrostreifenleiterantenne und gruppenantenne
GB9720148D0 (en) Gene silencing materials and methods
DE69840172D1 (de) Rna exportelement
NO994009D0 (no) Gensekvensator og metoder
DE69828963D1 (de) Wirstoffabgabe und gentherapiesystem
DE69836432D1 (de) Bildcoder und -decoder
DE59505847D1 (de) Pseudoceramide
BR9506832A (pt) N-pirazolilanilinas e n-pirazolilaminopiridinas
AP2001002189A0 (en) Genes and proteins and their uses
DE69942195D1 (de) Prozesssystem und -verfahren
DE69842206D1 (de) Echounterdrücker und echounterdrückungsverfahren
DK0967286T3 (da) Leucinaminopeptodase-gen
DE69926005D1 (de) Carbamat- und carbazatketolidantibiotika
DE69808732T2 (de) Architektur für teilbare warteschlangen und warteschlangenverfahren
DE29703645U1 (de) Spann- und Tragesystem
EP1142999A4 (fr) Proteine et adn associe
HUP0104954A3 (en) Prv-1 gene and the use thereof
FI972010A0 (fi) Arrangemang i en borrningsanordning
EP1111047A4 (fr) Nouvelle proteine et son adn
KR970056581U (ko) 완충슈타이크 아이젠
DE59812220D1 (de) Halte- und trageband
EP1122312A4 (fr) Nouvelle proteine war-1 et son gene
GB9818235D0 (en) Gene and use thereof
DE29714544U1 (de) Befestigungssystem für Koffer- und Gehäuserollen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application